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10 NEW INVESTIGATORS CHOSEN
FOR ASBMT TRAINING COURSE
Ten new clinicians and investiga-
tors have been selected to participate
in the first ASBMT Transplant Clinical
Research Training Course, to be held
in mid-July in Keystone, Colo.
The six-day course is designed to
assist fellows and young faculty in ca-
reer paths toward successful clinical
research in blood and marrow trans-
plantation. The participants were se-
lected competitively from among 30
submitted applications, each includ-
ing a proposed research project.
Major funding for the clinical re-
search training course is being pro-
vided by Amgen, Merck, PDL Bio-
Pharma, Genzyme Transplant and
Abbott Molecular.
The fellow-in-training participants
will be:
Ann Mullally, MD, Massachusetts
General Hospital, Boston
Phillippe Armand, MD, PhD, Dana-
Farber, Boston
Carlos Almeida Ramos, MD, M.D.
Anderson, Houston
Alana Kennedy-Nasser, MD, Baylor,
Houston
Kirsten Williams, MD, National Can-
cer Institute, Bethesda
Jeanne Palmer, MD, Duke, Durham
Guillermo J. Ruiz Delgado, MD,
Hospital Universitario, Monterrey,
Mexico
The junior faculty participants will
be:
Guenther Koehne, MD, PhD, Me-
morial Sloan-Kettering, New York
Carrie Kitko, MD, University of
Michigan, Ann Arbor
G. Doug Myers, MD, Baylor, Hous-
ton
The course directors are Daniel
Weisdorf, MD, of the University of
Minnesota, and Nelson Chao, MD, of
Duke University. They, together with
six other faculty members, will lead
the sessions, as well as share their
career stories and counsel. Free time
for rest, recreation and creative think-
ing is built into the schedule.
The concept of a clinical research
training course emanated from an
ASBMT Board of Directors strategic
planning retreat. “The board mem-
bers felt that existing fellowship pro-
grams don’t adequately train clinical
fellows in the principles of clinical re-
search in blood and marrow trans-
plantation,” said Armand Keating,
MD, past-president and chair of the
committee to develop the training
course.
“Training programs typically don’t
fully cover the principles of taking ba-
sic research findings from the labora-
tory to the clinic, nor do they ade-
quately prepare the best young
physicians for academic careers in
blood and marrow transplantation.
We expect the training course to ad-
dress those deficiencies and help
close the gap,” he said.
The faculty members for the trans-
plant clinical research training course
are:
● Chris Bredeson, MD, MSc, Medical
College of Wisconsin – clinical trial
development, monitoring and
data management
● Dr. Chao – mechanisms of GvHD,
graft manipulation, animal models
and grant writing/grantsmanship
● Corey Cutler, MD, MPH, Dana-Far-
ber Cancer Institute – GvHD, new
drug studies and translational
studies
● Armand Keating, MD, Princess
Margaret Hospital Cancer Center,
Toronto – stem cell biology, gene
therapy and translational studies
● Ginna Laport, MD, Stanford Uni-
versity – cancer trials, new agents
and multicenter trials
● Stephanie Lee, MD, MPH, Fred
Hutchinson Cancer Research Cen-
ter – quality of life/late effects
● Brent Logan, PhD, Center for In-
ternational Blood and Marrow
Transplant Research – statistics
● Jeffrey Miller, MD, University of
Minnesota – cellular and molecu-
lar mechanisms of immunologic
anti-cancer therapy
● Dr. Weisdorf – GvHD clinical and
translational trials and complica-
tions of transplant
WEB SITE GUIDES RESPONSE
FOR RADIATION INCIDENTS
A Web site for helping BMT physi-
cians respond to radiation incidents
has been created by the Radiation
Injury Treatment Network (RITN), a
joint project of the ASBMT and the
National Marrow Donor Program.
The Web site provides guidelines
and protocols for comprehensive
evaluation and treatment of victims of
radiation exposure or other marrow-
toxic injuries. The information is
based on more than 20 years of the
U.S. Navy’s leadership in contingency
preparedness through the NMDP
and was prepared by representatives
of transplant centers, donor centers
and cord blood banks. The groups
have been meeting since 2003 to
prepare for radiological or chemical
events that result in hematopoietic
toxicity.
The Web site address is www.
nmdp.org/RITN.
Designed for expansion and up-
date in the coming months, the Web
site compliments the Radiation Event
Medical Management (REMM) Web
site at remm.nlm.gov that was intro-
duced in March by the U.S. Depart-
ment of Health and Human Services.
Whereas the REMM site has a broad
focus on first-responder triage and
community and hospital-wide inci-
dent response, the RITN site is specific
to hematopoietic cell therapy.
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